BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2026.
"Solid start to 2026 – strong growth in CERAMENT® G in the US and improved cash flow." Torbjörn Sköld, CEO
JANUARY - MARCH 2026
- Net sales increased by 14 percent (31 percent at constant exchange rates) and amounted to SEK 324.0 million (283.5).
- The US segment reported a sales growth of 16 percent (35 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 9 percent (16 percent at constant exchange rates).
- The gross margin amounted to 92.2 percent (92.6).
- The adjusted operating result amounted to SEK 84.9 million (39.7). The reported operating result amounted to SEK 72.2 million (29.6).
- Earnings per share before dilution were SEK 0.81 (0.16).
- Earnings per share after dilution were SEK 0.80 (0.16).
EVENTS DURING THE QUARTER
- In February, the first US-based clinical pilot study reporting on surgical technique and outcomes of CERAMENT G in the area of bone infection resulting from trauma was published.
- In March, the first US clinical case series with focus on infection prevention for trauma patients was published.
EVENTS AFTER THE PERIOD
- The US CMS proposes improved reimbursement for the use of CERAMENT G, in complex orthopaedic infection surgery, and more specific identification codes for CERAMENT G and CERAMENT® V from 2027 onwards. The final decision is expected in late summer.
- The Company also communicated that CMS proposes NTAP for CERAMENT V as of October 1, 2026, provided that the US FDA grants the Company's De Novo application no later than April 30, 2026. If an FDA approval is granted at a later date, the Company plans to submit a new NTAP application with a possible compensation supplement from October 1, 2027.